LABELS · 2085d741-19ba-4115-bbe9-0debac82c204

TRODELVY

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-06-24
Captured: 2026-09-09T23:37:42.544548+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: NEUTROPENIA AND DIARRHEA TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia [see Dosage and Administration (2.4) ] . Initiate anti-infective treatment in patients with febrile neutropenia without delay [see Warnings and Precautions (5.1) ]. TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide [see Warnings and Precautions (5.2) ]. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses [see Dosage and Administration (2.4) ]. WARNING: NEUTROPENIA AND DIARRHEA See full prescribing information for complete boxed warning . TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia. Initiate anti-infective treatment in patients with febrile neutropenia without delay. ( 2.1 , 2.4 , 5.1 ) TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses. ( 2.4 , 5.2 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated: Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. ( 1.1 , 14.1 ) In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test. ( 1.1 , 14.1 ) Second Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. ( 1.1 , 14.1 ) Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ( 1.1 , 14.2 ) 1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor based therapy. TRODELVY, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥ 10)] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . Second Line or Later TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. 1.2 Locally Advanced or Metastatic HR-positive, HER2-negative Breast Cancer TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

Full extracted label fields

application numbers

BLA761115

boxed warning exact

WARNING: NEUTROPENIA AND DIARRHEA TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia [see Dosage and Administration (2.4) ] . Initiate anti-infective treatment in patients with febrile neutropenia without delay [see Warnings and Precautions (5.1) ]. TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide [see Warnings and Precautions (5.2) ]. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses [see Dosage and Administration (2.4) ]. WARNING: NEUTROPENIA AND DIARRHEA See full prescribing information for complete boxed warning . TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia. Initiate anti-infective treatment in patients with febrile neutropenia without delay. ( 2.1 , 2.4 , 5.1 ) TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses. ( 2.4 , 5.2 )

brand names

TRODELVY

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57a597d2-03f0-472e-b148-016d7169169d

generic names

SACITUZUMAB GOVITECAN

2085d741-19ba-4115-bbe9-0debac82c204

indications and usage exact

1 INDICATIONS AND USAGE TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated: Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. ( 1.1 , 14.1 ) In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test. ( 1.1 , 14.1 ) Second Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. ( 1.1 , 14.1 ) Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ( 1.1 , 14.2 ) 1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor based therapy. TRODELVY, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥ 10)] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . Second Line or Later TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. 1.2 Locally Advanced or Metastatic HR-positive, HER2-negative Breast Cancer TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

indications and usage tables exact

is original packager

true

manufacturer names

Gilead Sciences, Inc.

matched search terms

cancer
tumors

package ndcs

55135-132-01

product ndcs

55135-132

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Indications and Usage ( 1.1 ) 06/2026 Dosage and Administration ( 2.2 , 2.3 , 2.4 , 2.5 ) 06/2026 Warnings and Precautions ( 5.3 ) 06/2026

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

2360534
2360539

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00100.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA761115

brand names

TRODELVY

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 600
end exclusive: true
exact text: 1 INDICATIONS AND USAGE TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated: Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. ( 1.1 , 14.1 ) In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 0

current approval status

not_reconciled

duplicate text group

dup-1d28d0e3487f1fef0474

extraction review status

automated_candidate_pending_source_review

generic names

SACITUZUMAB GOVITECAN

ind-span-af9b34cc8974a98e3b68

label id

2085d741-19ba-4115-bbe9-0debac82c204

positive predicate support span

end: 110
end exclusive: true
exact text: is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 33

qualifier mentions

context exact
irst Line As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple neg
kind
age
polarity
not_inferred
span
end
248
end exclusive
true
exact text
adult patients
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
234
context exact
somerase inhibitor conjugate indicated: Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of a
kind
biomarker
polarity
not_inferred
span
end
175
end exclusive
true
exact text
Metastatic Triple-Negative Breast Cancer Fi
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
132
context exact
ent of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-base
kind
biomarker
polarity
not_inferred
span
end
330
end exclusive
true
exact text
metastatic triple negative breast cancer (T
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
287
context exact
ive breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy.
kind
biomarker
polarity
not_inferred
span
end
399
end exclusive
true
exact text
PD-L1 inhibitor-based therapy
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
370
context exact
d antibody and topoisomerase inhibitor conjugate indicated: Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line tr
kind
stage_or_setting
polarity
not_inferred
span
end
163
end exclusive
true
exact text
Locally Advanced or Metastatic Triple-Negative Brea
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
112
context exact
e agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for
kind
stage_or_setting
polarity
not_inferred
span
end
301
end exclusive
true
exact text
unresectable locally advanced or metastatic tri
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
254
context exact
ocally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
343
end exclusive
true
exact text
First Line As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
173
context exact
nced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy.
kind
regimen
polarity
not_inferred
span
end
361
end exclusive
true
exact text
As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
184

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 400
end exclusive: true
exact text: 1 INDICATIONS AND USAGE TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated: Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line As a single agent for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy.
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%222085d741-19ba-4115-bbe9-0debac82c204%22

spl effective date

2026-06-24

spl set id

57a597d2-03f0-472e-b148-016d7169169d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

BLA761115

brand names

TRODELVY

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 878
end exclusive: true
exact text: for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. ( 1.1 , 14.1 ) In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test. ( 1.1 , 14.1 ) Second Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for me
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 201

current approval status

not_reconciled

duplicate text group

dup-a2fcf902232fa1647249

extraction review status

automated_candidate_pending_source_review

generic names

SACITUZUMAB GOVITECAN

ind-span-37adc89fe3b77a82ab41

label id

2085d741-19ba-4115-bbe9-0debac82c204

positive predicate support span

end: 110
end exclusive: true
exact text: is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 33

qualifier mentions

context exact
berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose
kind
age
polarity
not_inferred
span
end
545
end exclusive
true
exact text
adult patients
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
531
context exact
ent of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test.
kind
biomarker
polarity
not_inferred
span
end
627
end exclusive
true
exact text
metastatic TNBC whose tumors express PD-L1
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
584
context exact
fa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an
kind
stage_or_setting
polarity
not_inferred
span
end
598
end exclusive
true
exact text
unresectable locally advanced or metastatic TNB
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
551
context exact
ab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
677
end exclusive
true
exact text
first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
507
context exact
( 1.1 , 14.1 ) In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by
kind
regimen
polarity
not_inferred
span
end
595
end exclusive
true
exact text
In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
416

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 678
end exclusive: true
exact text: ( 1.1 , 14.1 ) In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test.
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 401

source url

https://api.fda.gov/drug/label.json?search=id%3A%222085d741-19ba-4115-bbe9-0debac82c204%22

spl effective date

2026-06-24

spl set id

57a597d2-03f0-472e-b148-016d7169169d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · positive indication candidate

application numbers

BLA761115

brand names

TRODELVY

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1095
end exclusive: true
exact text: uronidase alfa-pmph for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-authorized test. ( 1.1 , 14.1 ) Second Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. ( 1.1 , 14.1 ) Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-posit
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 479

current approval status

not_reconciled

duplicate text group

dup-682e2e8baeac64a86668

extraction review status

automated_candidate_pending_source_review

generic names

SACITUZUMAB GOVITECAN

ind-span-ab63761128eaaee5adfe

label id

2085d741-19ba-4115-bbe9-0debac82c204

positive predicate support span

end: 110
end exclusive: true
exact text: is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 33

qualifier mentions

context exact
( 1.1 , 14.1 ) Second Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have receiv
kind
age
polarity
not_inferred
span
end
750
end exclusive
true
exact text
adult patients
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
736
context exact
or more prior systemic therapies, at least one of them for metastatic disease.
kind
biomarker
polarity
not_inferred
span
end
894
end exclusive
true
exact text
metastatic disease
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
876
context exact
cond Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one
kind
stage_or_setting
polarity
not_inferred
span
end
803
end exclusive
true
exact text
unresectable locally advanced or mTNBC who have
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
756
context exact
or more prior systemic therapies, at least one of them for metastatic disease.
kind
stage_or_setting
polarity
not_inferred
span
end
894
end exclusive
true
exact text
metastatic disease
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
876
context exact
( 1.1 , 14.1 ) Second Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
865
end exclusive
true
exact text
Second Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one o
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
694

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 895
end exclusive: true
exact text: ( 1.1 , 14.1 ) Second Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease.
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 679

source url

https://api.fda.gov/drug/label.json?search=id%3A%222085d741-19ba-4115-bbe9-0debac82c204%22

spl effective date

2026-06-24

spl set id

57a597d2-03f0-472e-b148-016d7169169d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 4 · unclassified context

application numbers

BLA761115

brand names

TRODELVY

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1517
end exclusive: true
exact text: cond Line or Later For the treatment of adult patients with unresectable locally advanced or mTNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. ( 1.1 , 14.1 ) Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ( 1.1 , 14.2 ) 1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable loc
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 696

current approval status

not_reconciled

duplicate text group

dup-0f2f7f1398752cf0bdd1

extraction review status

automated_candidate_pending_source_review

generic names

SACITUZUMAB GOVITECAN

ind-span-adc2a647af1caf3ca274

label id

2085d741-19ba-4115-bbe9-0debac82c204

positive predicate support span

Source null

qualifier mentions

context exact
-Positive, HER2-Negative Breast Cancer For the treatment of adult patients with unresectable locally advanced or metastatic hormone re
kind
age
polarity
not_inferred
span
end
1018
end exclusive
true
exact text
adult patients
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1004
context exact
( 1.1 , 14.1 ) Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer For the treatment of adult pat
kind
biomarker
polarity
not_inferred
span
end
953
end exclusive
true
exact text
Metastatic HR-Positive
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
931
context exact
( 1.1 , 14.1 ) Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer For the treatment of adult patients with unresectable locally advanced or me
kind
biomarker
polarity
not_inferred
span
end
999
end exclusive
true
exact text
HER2-Negative Breast Cancer For the treatmen
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
955
context exact
ent of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (
kind
biomarker
polarity
not_inferred
span
end
1098
end exclusive
true
exact text
metastatic hormone receptor (HR)-positive
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1057
context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received end
kind
biomarker
polarity
not_inferred
span
end
1163
end exclusive
true
exact text
HER2)-negative (IHC 0
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1142
context exact
erapy and at least two additional systemic therapies in the metastatic setting.
kind
biomarker
polarity
not_inferred
span
end
1316
end exclusive
true
exact text
metastatic setting
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1298
context exact
( 1.1 , 14.1 ) Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer For the treatment of adult pat
kind
stage_or_setting
polarity
not_inferred
span
end
953
end exclusive
true
exact text
Locally Advanced or Metastatic HR-Positive
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
911
context exact
tive Breast Cancer For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor r
kind
stage_or_setting
polarity
not_inferred
span
end
1071
end exclusive
true
exact text
unresectable locally advanced or metastatic hor
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1024
context exact
erapy and at least two additional systemic therapies in the metastatic setting.
kind
stage_or_setting
polarity
not_inferred
span
end
1316
end exclusive
true
exact text
metastatic setting
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1298
context exact
HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1316
end exclusive
true
exact text
who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1202

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1317
end exclusive: true
exact text: ( 1.1 , 14.1 ) Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 896

source url

https://api.fda.gov/drug/label.json?search=id%3A%222085d741-19ba-4115-bbe9-0debac82c204%22

spl effective date

2026-06-24

spl set id

57a597d2-03f0-472e-b148-016d7169169d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

BLA761115

brand names

TRODELVY

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1532
end exclusive: true
exact text: owth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ( 1.1 , 14.2 ) 1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced o
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 1118

current approval status

not_reconciled

duplicate text group

dup-c242a346a7287243c6e4

extraction review status

automated_candidate_pending_source_review

generic names

SACITUZUMAB GOVITECAN

ind-span-4dd77f9e8a46d57ff8d2

label id

2085d741-19ba-4115-bbe9-0debac82c204

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1332
end exclusive: true
exact text: ( 1.1 , 14.2 )
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 1318

source url

https://api.fda.gov/drug/label.json?search=id%3A%222085d741-19ba-4115-bbe9-0debac82c204%22

spl effective date

2026-06-24

spl set id

57a597d2-03f0-472e-b148-016d7169169d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · positive indication candidate

application numbers

BLA761115

brand names

TRODELVY

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1847
end exclusive: true
exact text: eptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ( 1.1 , 14.2 ) 1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor based therapy. TRODELVY, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metasta
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 1133

current approval status

not_reconciled

duplicate text group

dup-98d2de353f19c91f568c

extraction review status

automated_candidate_pending_source_review

generic names

SACITUZUMAB GOVITECAN

ind-span-8e46fea2b98d88750750

label id

2085d741-19ba-4115-bbe9-0debac82c204

positive predicate support span

end: 1448
end exclusive: true
exact text: is indicated
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 1436

qualifier mentions

context exact
a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple neg
kind
age
polarity
not_inferred
span
end
1495
end exclusive
true
exact text
adult patients
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1481
context exact
1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the fir
kind
biomarker
polarity
not_inferred
span
end
1400
end exclusive
true
exact text
Metastatic Triple-Negative Breast Cancer Fi
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1357
context exact
ent of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor base
kind
biomarker
polarity
not_inferred
span
end
1577
end exclusive
true
exact text
metastatic triple negative breast cancer (T
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1534
context exact
ive breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor based therapy.
kind
biomarker
polarity
not_inferred
span
end
1646
end exclusive
true
exact text
PD-L1 inhibitor based therapy
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1617
context exact
1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated
kind
stage_or_setting
polarity
not_inferred
span
end
1388
end exclusive
true
exact text
Locally Advanced or Metastatic Triple-Negative Brea
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1337
context exact
dicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for
kind
stage_or_setting
polarity
not_inferred
span
end
1548
end exclusive
true
exact text
unresectable locally advanced or metastatic tri
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1501
context exact
ocally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhib
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1568
end exclusive
true
exact text
First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1398
context exact
etastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor based therapy.
kind
regimen
polarity
not_inferred
span
end
1595
end exclusive
true
exact text
as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not c
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1418

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1647
end exclusive: true
exact text: 1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor based therapy.
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 1333

source url

https://api.fda.gov/drug/label.json?search=id%3A%222085d741-19ba-4115-bbe9-0debac82c204%22

spl effective date

2026-06-24

spl set id

57a597d2-03f0-472e-b148-016d7169169d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 7 · positive indication candidate

application numbers

BLA761115

brand names

TRODELVY

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2200
end exclusive: true
exact text: for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor based therapy. TRODELVY, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥ 10)] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . Second Line or Later TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least o
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 1448

current approval status

not_reconciled

duplicate text group

dup-4723c132640098591cc1

extraction review status

automated_candidate_pending_source_review

generic names

SACITUZUMAB GOVITECAN

ind-span-78bad01577efa1826cf6

label id

2085d741-19ba-4115-bbe9-0debac82c204

positive predicate support span

end: 1754
end exclusive: true
exact text: is indicated
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 1742

qualifier mentions

context exact
ase alfa-pmph, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose
kind
age
polarity
not_inferred
span
end
1801
end exclusive
true
exact text
adult patients
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1787
context exact
ent of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥ 10)] as determined by an FDA
kind
biomarker
polarity
not_inferred
span
end
1883
end exclusive
true
exact text
metastatic TNBC whose tumors express PD-L1
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1840
context exact
dicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥
kind
stage_or_setting
polarity
not_inferred
span
end
1854
end exclusive
true
exact text
unresectable locally advanced or metastatic TNB
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1807
context exact
zumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥ 10)] as determined by an FDA-authorized test [see Dosage and Administration (2
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1933
end exclusive
true
exact text
first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥ 10)] as determined
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1763
context exact
TRODELVY, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 [Combined Posi
kind
regimen
polarity
not_inferred
span
end
1837
end exclusive
true
exact text
in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with unresectable locally advanced
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
1658

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2000
end exclusive: true
exact text: TRODELVY, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥ 10)] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] .
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 1648

source url

https://api.fda.gov/drug/label.json?search=id%3A%222085d741-19ba-4115-bbe9-0debac82c204%22

spl effective date

2026-06-24

spl set id

57a597d2-03f0-472e-b148-016d7169169d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 8 · positive indication candidate

application numbers

BLA761115

brand names

TRODELVY

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2434
end exclusive: true
exact text: with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS ≥ 10)] as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] . Second Line or Later TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. 1.2 Locally Advanced or Metastatic HR-positive, HER2-negative Breast Cancer TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 1801

current approval status

not_reconciled

duplicate text group

dup-1cfe5860e03377123931

extraction review status

automated_candidate_pending_source_review

generic names

SACITUZUMAB GOVITECAN

ind-span-ece72d70bb510c86dd3b

label id

2085d741-19ba-4115-bbe9-0debac82c204

positive predicate support span

end: 2043
end exclusive: true
exact text: is indicated
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 2031

qualifier mentions

context exact
nd Line or Later TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who h
kind
age
polarity
not_inferred
span
end
2079
end exclusive
true
exact text
adult patients
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2065
context exact
ent of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metast
kind
biomarker
polarity
not_inferred
span
end
2161
end exclusive
true
exact text
metastatic TNBC who have received two or mo
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2118
context exact
or more prior systemic therapies, at least one of them for metastatic disease.
kind
biomarker
polarity
not_inferred
span
end
2233
end exclusive
true
exact text
metastatic disease
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2215
context exact
DELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at
kind
stage_or_setting
polarity
not_inferred
span
end
2132
end exclusive
true
exact text
unresectable locally advanced or metastatic TNB
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2085
context exact
or more prior systemic therapies, at least one of them for metastatic disease.
kind
stage_or_setting
polarity
not_inferred
span
end
2233
end exclusive
true
exact text
metastatic disease
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2215
context exact
Second Line or Later TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic diseas
kind
prior_therapy_or_line
polarity
not_inferred
span
end
2172
end exclusive
true
exact text
Second Line or Later TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior sy
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2001

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2234
end exclusive: true
exact text: Second Line or Later TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease.
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 2001

source url

https://api.fda.gov/drug/label.json?search=id%3A%222085d741-19ba-4115-bbe9-0debac82c204%22

spl effective date

2026-06-24

spl set id

57a597d2-03f0-472e-b148-016d7169169d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 9 · positive indication candidate

application numbers

BLA761115

brand names

TRODELVY

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2667
end exclusive: true
exact text: ndicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. 1.2 Locally Advanced or Metastatic HR-positive, HER2-negative Breast Cancer TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 2035

current approval status

not_reconciled

duplicate text group

dup-f927ffc9b6f16234950a

extraction review status

automated_candidate_pending_source_review

generic names

SACITUZUMAB GOVITECAN

ind-span-f0a6116a12fa680a5f0e

label id

2085d741-19ba-4115-bbe9-0debac82c204

positive predicate support span

end: 2332
end exclusive: true
exact text: is indicated
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 2320

qualifier mentions

context exact
ve Breast Cancer TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone re
kind
age
polarity
not_inferred
span
end
2368
end exclusive
true
exact text
adult patients
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2354
context exact
1.2 Locally Advanced or Metastatic HR-positive, HER2-negative Breast Cancer TRODELVY is indicated for the
kind
biomarker
polarity
not_inferred
span
end
2281
end exclusive
true
exact text
Metastatic HR-positive
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2259
context exact
1.2 Locally Advanced or Metastatic HR-positive, HER2-negative Breast Cancer TRODELVY is indicated for the treatment of adult patients with unresectable
kind
biomarker
polarity
not_inferred
span
end
2327
end exclusive
true
exact text
HER2-negative Breast Cancer TRODELVY is indi
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2283
context exact
ent of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (
kind
biomarker
polarity
not_inferred
span
end
2448
end exclusive
true
exact text
metastatic hormone receptor (HR)-positive
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2407
context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received end
kind
biomarker
polarity
not_inferred
span
end
2513
end exclusive
true
exact text
HER2)-negative (IHC 0
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2492
context exact
erapy and at least two additional systemic therapies in the metastatic setting.
kind
biomarker
polarity
not_inferred
span
end
2666
end exclusive
true
exact text
metastatic setting
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2648
context exact
1.2 Locally Advanced or Metastatic HR-positive, HER2-negative Breast Cancer TRODELVY is indicated for the
kind
stage_or_setting
polarity
not_inferred
span
end
2281
end exclusive
true
exact text
Locally Advanced or Metastatic HR-positive
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2239
context exact
DELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor r
kind
stage_or_setting
polarity
not_inferred
span
end
2421
end exclusive
true
exact text
unresectable locally advanced or metastatic hor
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2374
context exact
erapy and at least two additional systemic therapies in the metastatic setting.
kind
stage_or_setting
polarity
not_inferred
span
end
2666
end exclusive
true
exact text
metastatic setting
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2648
context exact
HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
2666
end exclusive
true
exact text
who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting
label id
2085d741-19ba-4115-bbe9-0debac82c204
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start
2552

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2667
end exclusive: true
exact text: 1.2 Locally Advanced or Metastatic HR-positive, HER2-negative Breast Cancer TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
label id: 2085d741-19ba-4115-bbe9-0debac82c204
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 60dfa0b723f1bde259dfaeb4391c7a18bec60f1b0b5654fc8ba590a0da098c28
start: 2235

source url

https://api.fda.gov/drug/label.json?search=id%3A%222085d741-19ba-4115-bbe9-0debac82c204%22

spl effective date

2026-06-24

spl set id

57a597d2-03f0-472e-b148-016d7169169d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice